Tumoricidal Effects of Activated Macrophages in a Mouse Model of Chronic Lymphocytic Leukemia

被引:25
|
作者
Wu, Qing-Li [1 ]
Buhtoiarov, Ilia N. [2 ]
Sondel, Paul M. [2 ,3 ]
Rakhmilevich, Alexander L. [2 ]
Ranheim, Erik A. [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA
来源
JOURNAL OF IMMUNOLOGY | 2009年 / 182卷 / 11期
基金
美国国家卫生研究院;
关键词
ANTI-CD40; MONOCLONAL-ANTIBODY; PRO-INFLAMMATORY CYTOKINE; NITRIC-OXIDE SYNTHASE; CD154; GENE-THERAPY; B-CELLS; DOWN-REGULATION; CD40; LIGATION; IMMUNE-SYSTEM; TUMOR-CELLS; APOPTOSIS;
D O I
10.4049/jimmunol.0801847
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The E mu-TCL1 transgenic mouse spontaneously develops a CD5(+) B cell lymphoproliferative disorder similar to human chronic lymphocytic leukemia (CLL). Given the ineffectual T cell antitumor responses in this mouse model of CLL, we sought to determine whether combined treatment with anti-CD40 mAb (alpha CD40) and CpG-containing oligodeoxynucleotides (CpG) could exert immunotherapeutic effects. We have previously shown that macrophages activated by sequential ligation of CD40 and TLR9 could become cytotoxic against solid tumor cell lines both in vitro and in vivo. In the current study, we find that alpha CD40 plus CpG-activated macrophages induce tumor B cell apoptosis in vitro and that alpha CD40 plus CpG treatment markedly retards tumor growth in immunodeficient SCID/Beige mice following transplantation of primary tumor B cells. Our results suggest a novel immunotherapeutic strategy for CIA, that may be effective even in the face of tumor or chemotherapy-induced T cell immunodeficiency. The Journal of Immunology, 2009, 182: 6771-6778.
引用
收藏
页码:6771 / 6778
页数:8
相关论文
共 50 条
  • [1] THE NZB MOUSE AS A MODEL FOR CHRONIC LYMPHOCYTIC-LEUKEMIA
    PHILLIPS, JA
    MEHTA, K
    FERNANDEZ, C
    RAVECHE, ES
    CANCER RESEARCH, 1992, 52 (02) : 437 - 443
  • [2] The TCL1 mouse as a model for chronic lymphocytic leukemia
    Hamblin, Terry J.
    LEUKEMIA RESEARCH, 2010, 34 (02) : 135 - 136
  • [3] The Eμ-TCL-1 mouse model of chronic lymphocytic leukemia
    Chin, H. S.
    Egle, A.
    Khaw, S. L.
    Van Delft, M. F.
    Huang, D. C.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S110 - S110
  • [4] TUMORICIDAL PROPERTIES OF INVITRO ACTIVATED MACROPHAGES
    FIDLER, I
    DARNELL, J
    JOURNAL OF THE RETICULOENDOTHELIAL SOCIETY, 1976, 20 (06): : A39 - A39
  • [5] Expression and Effects of Ligand-activated Estrogen Receptors in Chronic Lymphocytic Leukemia
    Hasni, Mohammad Sharif
    Yakimchuk, Konstantin
    ANTICANCER RESEARCH, 2019, 39 (01) : 167 - 172
  • [6] EFFECTS OF INHIBITORS OF TUMORICIDAL ACTIVITY UPON SCHISTOSOMULUM KILLING BY ACTIVATED MACROPHAGES
    JAMES, SL
    GLAVEN, JA
    INFECTION AND IMMUNITY, 1987, 55 (12) : 3174 - 3180
  • [7] The New Zealand Black Mouse as a Model for the Development and Progression of Chronic Lymphocytic Leukemia
    Salerno, Erica
    Yuan, Yao
    Scaglione, Brian J.
    Marti, Gerald
    Jankovic, Alexander
    Mazzella, Fermina
    Laurindo, Maria Fernanda
    Despres, Daryl
    Baskar, Sivasubramanian
    Rader, Christoph
    Raveche, Elizabeth
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2010, 78B : S98 - S109
  • [8] TUMORICIDAL CAPACITY OF ARTIFICIALLY ACTIVATED MURINE MACROPHAGES
    ATKINSON, WB
    BASS, PA
    ATKINSON, GB
    BLACK, CL
    HARVEY, AM
    JOURNAL OF LEUKOCYTE BIOLOGY, 1984, 36 (02) : 219 - 219
  • [9] DISSOCIATION OF TUMORICIDAL AND LISTERICIDAL FUNCTIONS OF ACTIVATED MACROPHAGES
    DEBATIN, KM
    GEMSA, D
    IMMUNOBIOLOGY, 1982, 162 (4-5) : 341 - 341
  • [10] Lipids and Their Effects in Chronic Lymphocytic Leukemia
    Friedman, Daphne R.
    EBIOMEDICINE, 2017, 15 : 2 - 3